World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
41053
World Ranking
17796
National Ranking
274

Overview

Karen N. Price is affiliated with the Frontier Science Foundation in Switzerland. Their research primarily focuses on the intersection of biochemistry, genetics, and molecular biology, with a concentration on aging and related physiological processes.

The scientist's work covers several subfields including aging, physiology, and the endocrine and autonomic systems. Their research topics revolve around genetics, aging, and longevity in model organisms, dietary effects on health, and circadian rhythm and melatonin.

Key recent publications by Karen N. Price include:

  • Food odors decrease longevity via a brain-gut axis, 2021, Nature Aging
  • Metabolic state modulates risky foraging behavior via multiple branches of the insulin/IGF-1-like pathway in C. elegans, 2025, bioRxiv (Cold Spring Harbor Laboratory)

Their frequent coauthors include:

  • Michael N. Nitabach
  • Jason T. Braco
  • Pooja Sareen
  • Peter J. Niesman

Karen N. Price's research has been published mainly in Nature Aging and bioRxiv (Cold Spring Harbor Laboratory).

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

    B A Gusterson;R D Gelber;A Goldhirsch;K N Price

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

    Henning Mouridsen;Anita Giobbie-Hurder;Aron Goldhirsch;Beat Thürlimann

  • Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98

    Giuseppe Viale;Meredith M. Regan;Eugenio Maiorano;Mauro G. Mastropasqua

  • Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

    Marco Colleoni;Zhuoxin Sun;Karen N. Price;Per Karlsson

  • Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials

    Bernhard C. Pestalozzi;David Zahrieh;Elizabeth Mallon;Barry A. Gusterson

  • Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

    Meredith M Regan;Patrick Neven;Anita Giobbie-Hurder;Aron Goldhirsch

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

    Giuseppe Viale;Anita Giobbie-Hurder;Meredith M. Regan;Alan S. Coates

  • Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

    Bernhard C. Pestalozzi;D. Zahrieh;K. N. Price;S. B. Holmberg

  • Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII

    Diana Crivellari;Marco Bonetti;Monica Castiglione-Gertsch;Richard D. Gelber

  • Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

    Otto Metzger-Filho;Zhuoxin Sun;Giuseppe Viale;Karen N. Price

  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

    Sherene Loi;Anita Giobbie-Hurder;Andrea Gombos;Thomas Bachelot

  • CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

    Meredith M. Regan;Brian Leyland-Jones;Mark Bouzyk;Olivia Pagani

Frequent Co-Authors

Richard D. Gelber
Richard D. Gelber Harvard University
Alan S. Coates
Alan S. Coates University of Sydney
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Marco Colleoni
Marco Colleoni European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
Giuseppe Viale
Giuseppe Viale University of Milan
John F. Forbes
John F. Forbes University of Limerick
Martin F. Fey
Martin F. Fey University of Bern
Gini F. Fleming
Gini F. Fleming University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways that may interest you. For those aiming to enter nursing, it’s worth exploring nursing schools that don't require teas or hesi. These programs help simplify the admissions process for aspiring nurses by removing standardized exam hurdles.

Healthcare administration is another promising field. Many students are choosing accelerated healthcare programs that allow you to complete your degree faster and begin your career sooner. For existing nurses, bridge programs like asn to fnp support advancement from an Associate Degree in Nursing to a Family Nurse Practitioner role.

Another growing sector is nutrition and wellness. Earning an online bs in nutrition can open opportunities in clinical, community, or food industry settings. Each of these pathways offers flexibility through online study, helping you tailor your education to your career goals.

Best Scientists Citing Karen N. Price

Trending Scientists